Methods of using a methylxanthine compound
View Patent ↗The invention relates to compositions and methods for treating various diseases or medical conditions by administering a methylxanthine compound. Specifically, the invention relates to compositions and methods for treating cytochrome oxidase (CcOX) mediated diseases or medical conditions by administering compositions comprising a methyl xanthine compound.
1. A method of treating a subject afflicted with sepsis-associated myocardial depression, comprising the step administering to said subject a composition comprising a therapeutically effective amount of a methylxanthine compound.
2. The method of claim 1 , whereby said methylxanthine compound is caffeine.
3. The method of claim 1 , whereby said methylxanthine compound increases cytochrome oxidase (CcOX) activity in a cell in said subject.
4. The method of claim 2 , whereby the composition comprises between about 0.5 and 20 mg/kg/day caffeine.
5. The method of claim 1 , whereby the step of administering is via intraperitoneal, parenteral, subcutaneous, intravenous injection.
6. A method of increasing the survival of a subject afflicted with sepsis associated myocardial dysfunction, comprising the step administering to said subject a composition comprising a therapeutically effective amount of a methylxanthine compound.
7. The method of claim 6 , whereby said methylxanthine compound is caffeine.
8. The method of claim 6 , whereby said methylxanthine compound increases cytochrome oxidase (CcOX) activity in a cell in said subject.
9. The method of claim 7 , whereby the composition comprises between about 0.5 and 10 mg/kg/day caffeine.
10. A method of inhibiting or suppressing sepsis associated myocardial dysfunction in a subject in need thereof, comprising the step administering to said subject a composition comprising a therapeutically effective amount of a methylxanthine compound.
11. The method of claim 10 , whereby said methylxanthine compound is caffeine.
12. The method of claim 10 , whereby said methylxanthine compound increases cytochrome oxidase (CcOX) activity in a cell in said subject.
13. The method of claim 11 , whereby 0.5-20 mg/kg/day caffeine is administered to said subject.
14. A method of reducing the symptoms associated with sepsis associated myocardial dysfunction in a subject in need thereof, comprising the step administering to said subject a composition comprising a therapeutically effective amount of a methylxanthine compound.
15. The method of claim 14 , whereby said methylxanthine compound is caffeine.
16. The method of claim 14 , whereby said methylxanthine compound increases cytochrome oxidase (CcOX) activity in a cell in said subject.
17. The method of claim 15 , whereby the composition comprises between about 0.5 and 20 mg/kg/day caffeine.
18. The method of claim 1 , wherein the methylxanthine compound is theobromine or theophylline.
19. The method of claim 6 , wherein the methylxanthine compound is theobromine or theophylline.
20. The method of claim 10 , wherein the methylxanthine compound is theobromine or theophylline.
21. The method of claim 14 , wherein the methylxanthine compound is theobromine or theophylline.